Xalatan  (U.S.N.L.M.)
Dosing 1 drop qpm (optimal),          (AM dosing is considered acceptable.)
Chem Specs latanoprost 0.005%
Quantities 2.5ml
Cost 44.46     generic
Class prostaglandin analog (as an isopropyl ester prodrug)
Action Increased uveoscleral aqueous outflow (possibly by loosening intercellular spaces.)
28% - 30% IOP reduction
Usage Indicated for reduction of IOP in open angle glaucoma or ocular hypertension.
IOP reduction starts in 3-4 hours. Maximum effect in 8–12 hours.
Side Effects Generally less hyperemia, less pigmentation of iris, lids, and lashes than Lumigan.
Possible cystoid macular edema in pseudophakes and/or aphakes. May exacerbated
iritis/uveitis. Possible reactivation of herpes simplex and zoster. Dry eye-like surface
inflammation observed in mice.1
Avoid with inflammatory glaucomas and surface eye disease.
Contraindications Hypersensitivity to Xalantan or any other ingredient in the product.
Pediatric use Safety and effectiveness in pediatric patients have not been established.
Has been used in children as young as 5 yrs without notable problems.2
Pregnancy Category C   Embryofetal lethality shown in rats and rabbits at clinically relevant doses.
0.05% BAK preserved.
IOP lowering effects, drop size, and ingredient dosage in the generic has been questioned.
Narayanaswamy A, Neog A, Baskaran M, et al., Indian J Ophthalmol 2007;55:127–31
1. Yang Y, et al. Invest Ophthalmol Vis Sci. July 2018, Vol.59, 3375-3384
2. Younus M, et al. Am J Ophthalmol. 2018;doi:10.1016/j.ajo.2018.08.039.
    N.L.M. DailyMed page for Trusopt          PDR page for Trusopt